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Abstract 20 Haemagglutinin (HA) and neuraminidase (NA) surface glycoproteins of bat influenza H17N10 21 virus neither bind nor cleave sialic acid receptors, indicating this virus employs cell-entry 22 mechanisms distinct from those of classical influenza A viruses. We observed that certain 23 human haematopoietic cancer cell lines and the canine MDCK II cells are susceptible to H17-24 pseudotyped viruses. We identified the human HLA-DR receptor as an entry-mediator for 25 H17-pseudotypes, suggesting that H17N10 possesses zoonotic potential.  26 
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Main  27 Bats are reservoirs of diverse, potentially zoonotic viruses (e.g. Paramyxoviridae, 28 
Coronaviridae, Filoviridae), further exemplified by the discovery of the evolutionarily distinct, 29 influenza A-like viruses H17N10 and H18N11 (BatIVs) in asymptomatic bats1,2. This discovery 30 led to concern that bats may be neglected reservoirs of influenza viruses3.  31 The natural reservoir of classical influenza A viruses (IAVs) is aquatic birds, from which they 32 emerge, via genome reassortment and mutation, to cause sporadic pandemics in humans and 33 other hosts4. The initial cross-species barrier is host cell attachment. The HA mediates virus 34 binding to host-specific sialic acid (SA) moieties4. The crystal structures of BatIV HAs exhibit 35 divergence of their protein conformations from those of IAVs and inability to accommodate 36 SA2,5,6. Initial efforts to isolate infectious BatIVs from bats failed, mainly because their 37 receptors were unknown1,2,5,7,8. Synthetic BatIVs were able to infect mammalian cell lines9-11. 38 Identifying the BatIV receptors is key to assessing their zoonotic risk.  39  40 Lentivirus-derived pseudotypes (PV) with heterologous envelope proteins have facilitated 41 identification of viral receptors12 and are valuable in assessing H17N10 tropism12,13. We have 42 shown that transduction-competent H17- and H17N10-PV are recovered from HEK293T/17 43 cells only in the presence of proteases (HAT or TMPRSS2) (Fig. 1a)13, in keeping with 44 published data11. To study the distribution of the H17N10 receptor(s), a panel of cell lines 45 (Supplementary Table 1) was challenged with H17–PV, assaying transduction via the 46 expression of PV-encoded luciferase reporter. PV bearing H5 (H5-PV) or VSV-G (VSV-G-PV) 47 served as positive controls; PV without envelope protein (Δ-env) as negative. H17-PV 48 displayed highly limited species/cell tropism, in agreement with previous work9-11, suggesting 49 the receptor(s) are not ubiquitous (Fig. 1b). Canine MDCK II (unlike MDCK I) cells are 50 susceptible to H17-PV (Fig. 1c) in agreement with previous studies10,11. MDCK II cells were 51 not susceptible to PV expressing N10 alone while particles bearing H17 alone or both H17 and 52 
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N10 transduced these cells with high, comparable efficiency, indicating that N10 is 53 dispensable for entry, in keeping with published data9,11. To characterise the H17 putative 54 receptor(s), MDCK II cells were (pre)-treated with enzymatic agents before transduction (Fig. 55 1d). Pre-treatment with neuraminidase, which cleaves surface SA, reduced transduction by 56 H5-PV (by 68-86%) but not H17-PV, further supporting the notion that SA are not the H17-57 receptors8-11.  58  59 IAVs primarily enter cells via endocytosis followed by low pH-triggered endosomal fusion. 60 Treatment of cells with ammonium chloride blocked uptake of H5- and H17-PV, 61 demonstrating that entry of H17, like IAVs, is pH-dependent consistent with a previous 62 study9. Entry of H17-PV was more affected than H5-PV by pre-treatment of cells with 63 proteases or an inhibitor of N-glycosylation (reduced by up to 72 and 78%, compared to 45 64 and 20%, respectively), supporting the supposition9 that the H17-receptor(s) is a 65 glycoprotein.  66  67 MDCK cells are heterogeneous, displaying phenotypic variation14, with MDCK I and II 68 representing early and late passages of the parental NBL-2 cells. Transcriptional differences 69 between early (passage 8) and late (passage 21) MDCKs were investigated using microarrays, 70 identifying 17 differentially regulated transcripts (Fig. 2a). Using transmembrane domain and 71 subcellular localisation prediction algorithms, we identified the dog leukocyte antigen DRα-72 chain (DLA-DRA) as the only transcript encoding a surface-anchored protein, over-expressed 73 in late, compared to early, passage cells (Supplementary Table 2). Significant over-expression 74 of DLA-DRA (and paralogue DLA-DRB1) was confirmed by qRT-PCR in MDCK II compared to I 75 cells (Fig. 2b).   76  77 
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DLA-DRA is a well-conserved orthologue of the human MHC-II HLA-DRA (Supplementary 78 Figure 1). MHC-II molecules are heterodimers of two glycosylated, transmembrane 79 polypeptide chains (monomorphic α and polymorphic β), expressed selectively on antigen 80 presenting cells (APCs; Fig. 2c). HLA-DR forms complexes, with endocytosed foreign 81 peptides, which are presented to CD4+ T-helper cells for recognition15.  82 To assess the zoonotic potential of H17N10, we explored the H17-PV tropism using human 83 cell lines with known elevated HLA-DR expression levels15 (Fig. 2d). Burkitt’s lymphoma-84 derived Raji, Ramos and BJAB B-lymphocytes and the B-lymphoblastoid cells (B-LCL) show 85 decreasing susceptibility, in that order, to H17-PV. Kasumi-1 leukaemic cells showed marginal 86 susceptibility, while Molt-4 and HL-60 leukaemic cells, Jurkat T-cells, pro-monocytic THP-1 87 and U-937, and primary B-cells showed no susceptibility to H17-PV. Differential susceptibility 88 to H17-PV correlated with HLA-DRA expression levels (confirmed by qRT-PCR). Surface 89 expression of the heterodimer was assayed by flow cytometry (Fig. 2e)16 and showed an 90 association with susceptibility to H17-PV. 91   92 We investigated whether ectopic expression of HLA-DR was sufficient to render non-APC 93 susceptible to H17-PV. HEK293T/17 cells were transiently co-transfected with the DRA and 94 DRB1 expression vectors. Surface expression of the heterodimer was confirmed via 95 immunofluorescence (Supplementary Figure 2). Flow cytometry confirmed 47% of cells 96 formed a functional surface heterodimer (Fig. 2f). Over-expression of HLA-DR resulted in 97 significant transduction by H17-PV. Furthermore, transduction was enhanced two-fold (Fig. 98 2g) in cells FACS-enriched for HLA-DR. Similar results were obtained using bat cells 99 (Supplementary Figure 3). Conversely, small interfering RNA targeting HLA-DRA (Fig. 2h) or 100 MHC-II monoclonal antibodies (Fig. 2i; Supplementary Figure 4) drastically reduced Raji cells’ 101 susceptibility to H17-PV.  102  103 
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Together, these findings demonstrate HLA-DR functions as a bona fide entry mediator for 104 H17N10. Similarly, Karakus et al determined that bat, pig, mouse or chicken HLA-DR 105 orthologues mediate cell entry of H18N1117. Through efficient binding to HLA-DR, BatIVs 106 might simultaneously access APCs and block T-cell responses. This might explain the viruses’ 107 survival and asymptomatic status in carrier bats.  108 With limited functional information available on bat MHC-II, its role in the pathogenesis and 109 transmission of BatIVs remains obscure. Nevertheless, the observation that H17N10 can 110 enter human HLA-DR+ cells implies that the virus has zoonotic potential.  111 
 112 
Methods 113 
Cell culture and treatment 114 Cell lines are described in Supplementary Table 1 and were cultured according to standard 115 protocols (www.atcc.org). Bat cell lines were propagated in DMEM supplemented with heat-116 inactivated 15% fetal bovine serum (Life Technologies), penicillin (100 U/ml) and 117 streptomycin (100 μg/ml; Invitrogen) and maintained at 37°C and 5% CO2. 118 MDCK II cells were treated as previously9 with either the endosomal acidification reagent 119 ammonium chloride (1-100 mM), or pre-treated with neuraminidase from Clostridium 120 
perfrigens for 2 h (1-100 mM) or pronase for 30 min (endo- 121 and exoproteases from Streptomyces griseus at 5-50 μg/ml; Calbiochem), or an N-122 glycosylation inhibitor for 5 h (tunicamycin at 0.01-1 μg/ml; Sigma-Aldrich). For experiments 123 using glycosidases, Raji and Ramos cells were treated as previously18 with 0-100 U/ml 124 Peptide:N-glycosidase F (PNGase F; Calbiochem) or endoglycosidase H (endo H; New England 125 Biolabs) or a mixture of neuraminidase (50 mM) and O-glycosidase (1-20 mU/ml) in Hank’s 126 Balanced Salt Solution (HBSS; Sigma) for 2 h at 37°C. Cells were washed twice with HBSS and 127 transduced with H17- and VSV-G-PV for 2 h. The cells were then resuspended in fresh growth 128 
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medium for 24-48 h before assay. Bafilomycin A1 (Calbiochem) was used at a concentration 129 of 10 nM. Cell viabilities were assessed by a trypan blue exclusion test.  130 
 131 
Pseudotype production and susceptibility assays 132 Pseudotypes expressing H17 and N10 (from A/little yellow-shouldered 133 bat/Guatemala/060/2011), H5 (A/Vietnam/1194/2004; H5N1 clade 1) or VSV (Vesicular 134 Stomatitis Virus)-G glycoproteins were produced as described13. Briefly, the lentiviral 135 packaging plasmid p8.91, the pCSFLW firefly luciferase vector, the pI.18 expression plasmids 136 for H17 and/or N10 and the protease encoding plasmid pCAGGS-HAT were co-transfected 137 using polyethylenimine (PEI) reagent (Sigma-Aldrich) into HEK293T/17 cells. Filtered 138 supernatants were collected 48-72 h post transfection. To remove viral titer bias between 139 different stocks, PV were concentrated and (re-) titrated by serial dilution. Concentration was 140 carried out by ultra-centrifugation for 2 h at 25,000 rpm at 4°C (Beckman Optima XL-100 K 141 Ultracentrifuge).                                                                                                 142 Two-fold serial dilutions of PV-containing supernatant were performed as previously 143 described13 using 96-well plates. Subsequently, 1x104 (for adherent) and 3x104 cells (for 144 suspension) cells were added in 50 µl of medium per well.  Plates were incubated for 24-48 h, 145 after which 50 µl of Bright-Glo™ substrate (Promega) was added. Luciferase readings were 146 conducted with a luminometer (FLUOstar OPTIMA, BMG Labtech) after a 5-min incubation. 147 Data was normalized using Δ–env and cell-only measurements and expressed as Relative 148 Luminescence Units (RLU)/ml.  149 
 150 
Plasmids and transfections 151 Expression plasmids for HLA-DRA (NM_019111) and HLA-DRB1 (NM_001243965) were 152 purchased from GenScript. HEK293T/17 at sub-confluence in 6-well plates or 100 mm 153 dishes were transfected with HLA-DRA or HLA-DRB1 plasmids or a 1:1 combination of both 154 
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using Lipofectamine 3000 (Thermo Fisher). 48 h after transfection, cells were used either 155 for immunofluorescence analysis, for FACS analysis or for PV-transduction. The 156 transfection efficiency, as assessed by the GFP expression of a control plasmid, was >70% 157 under microscopic observation. PakiTO3 cells were transfected with HLA-DR plasmids and 158 selected with geneticin (500 μg/ml).  159  160  Microarray analysis 161 Total RNA was isolated from triplicates of early and late passage MDCK cells using a Ribopure 162 kit (Ambion). Preparation of samples and hybridization to Affymetrix Canine Genome 2.0 163 GeneChips was performed according to standard Affymetrix protocols. A one-way ANOVA 164 adjusted with the Benjamini–Hochberg multiple-testing correction (p<0.05) was performed 165 with Partek Genomics Suite (v6.6) as previously described19.  166  167 
HLA-DRA knockdown and blocking using siRNA and monoclonal antibodies 168 A Sigma-Aldrich MISSION endonuclease-derived esiRNA (EHU226621) was used to knock 169 down HLA-DRA expression in Raji cells. Lipofectamine RNAiMAX reagent (Thermo Fisher) 170 was used to transfect exponentially grown cells with 50 nM of siHLA-DRA or of siControl 171 (SIC001). Initial transfection was followed by re-transfection of cells on the following day. 172 Cells were collected after 48 h and either seeded for transduction with PV or processed in 173 order to validate siRNA activity (by qRT-PCR and western blot).  174 To evaluate the interaction of HLA-DR with H17, we used the broadly reactive MHC-II mAb 175 WR18 (Biorad; code MCA477) and anti-HLA-DR mAb (clone 302CT2, Enzo Life Sciences). 176 After 1 h pre-incubation with increasing mAb concentrations of the antibody, Raji cells 177 (3x104) were transduced for 2 h with H17-or VSV-G-PV. The cells were then resuspended in 178 fresh growth medium and luciferase was measured after 24 h. 179 
 180 
 8
Western blot analysis  181 Washed cells were lysed on ice with lysis buffer [0.5% NP40 in PBS with 10 mM Tris-HCl, pH 182 7.4 supplemented with protease inhibitors (Thermo Fisher)] and protein was quantified by 183 the BCA assay kit (Thermo Fisher). 20-50 μg of protein was electrophoresed on a 4-15% 184 sodium dodecylsulfate polyacrylamide gel, alongside a protein ladder (Bio-Rad) and 185 immunoblotted with the mouse mAb anti-HLA-DRA (1:1000; clone: 302CT2, Enzo Life 186 Sciences) or rabbit mAb a-tubulin (1:2000; Cell signalling Technology). The membranes were 187 washed and incubated with goat anti-rabbit or donkey anti-mouse secondary antibodies (LI-188 COR) in the dark for 1 h. Scanning was carried out using the Odyssey Imaging system.  189  190 
Immunofluorescence 191 Transfected cells were seeded onto glass cover slips overnight and were fixed with 4% 192 paraformaldehyde. Fixed cells were then washed and permeabilised with 1% Triton X-100 in 193 PBS for 10 minutes. After washing, the cover slips were incubated with a mouse HLA-DRA 194 mAb (169-1B5.2; Bio-Techne) targeting a monomorphic HLA-DR framework determinant for 195 1 hr, washed and incubated with anti-mouse Alexafluor488 conjugated-Ab (Thermo Fisher) 196 for 30 minutes. Cover slips were mounted using Prolong Gold containing DAPI (Invitrogen). 197 Images were acquired on EVOS fluorescent microscope (Life Technology). Experiments were 198 carried out in duplicate. 199  200 
Flow cytometry  201 For surface staining, cells were washed twice in ice-cold FACS buffer and stained with a FITC-202 conjugated anti-human HLA-DR mAb (clone Tü36; BDIS), which binds to a monomorphic 203 epitope of the αβ complex and not the isolated α or β chains or the HLA-DP and -DQ 204 isotypes16. The BD LSR Fortressa was used to determine expression of HLA-DR, in 205 combination with the matched isotype control and cells were sorted into HLA-DR- and HLA-206 
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DR+ subpopulations with a FACS Aria cell sorter (BDIS). The Hoechst 33342 stain was used for 207 cell viability discrimination and the data files were analyzed using FlowJo software v10.0 208 (Tree Star, Inc.). Experiments were carried out in duplicate. Gating strategy: cells were first 209 identified by forward (FSC-Area) versus side scatter (SSC-Area) gating based on cell size and 210 granularity, then the FSC-Area vs FSC-Height gating for single cells. Dead cells were excluded 211 by gating on Hoechst 3342 negative cells. Positive and negative gates for HLA-DR expression 212 were determined by using isotype and unstained controls. 213 
 214 
qRT-PCR analysis 215 qRT-PCR was performed using procedures described previously19. qRT-PCR was conducted in 216 a 384-well plate with the ABI-7900HT system (Applied Biosystems). The following primers 217 were used: DLA-DRA (Forward: 5’-GCTGTGGACAAAGCTAACCTTG-3’, Reverse: 5’-218 TCTGGAGGTACATTGGTGTTCG-3’), DLA-DRB1 (Forward: 5’-AGCACCAAGTTTGACAAGC-3’, 219 Reverse: 5-AAGAGCAGACCCAGGACAAAG-3’). Absolute copy numbers of HLA-DRA were 220 calculated using a standard curve of known concentrations of the corresponding expression 221 plasmid. HLA-DRA (Forward: 5′-TCAAGGGATTGCGCAAAAGC-3′, Reverse: 5′- 222 ACACCATCACCTCCATGTGC-3′).  223  224 
Bioinformatic and statistical analyses 225 Phobius20 and TMHMM v2.021 software were used to predict the existence of transmembrane 226 domains and Deeploc-1.022 was used to determine sub-cellular protein localisation. The 227 amino acid sequences of DLA-DRA (NP_001011723.1), HLA-DRA (NP_061984.2), and their bat 228 orthologues [(Pteropus alecto (XP_006907484.1); Desmodus rotundus (XP_024413747.1)] 229 were subjected to multiple alignment using CLC workbench 7. Graphical representation and 230 statistical analyses were performed using Prism 8 (GraphPad). Unless otherwise stated, 231 results are shown as means ± SEM from three independent experiments. Selection of 232 
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statistical analysis was based on the data distribution. Data distributions were tested 233 for normality using the Shapiro–Wilk normality test. p<0.05 was considered significant unless 234 otherwise stated.  235 
 236 
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Figure Legends 275 
Figure 1: a. PV-production schematic. b. H17-PV transduction efficiencies in cell lines (n=6). 276 Relative Luminescence Units (RLU)/ml are plotted as box-plots (Upper/lower bounds: 25% 277 and 75% quantiles; middle band: median; whiskers: minimum-maximum values). c. PV-278 transduction efficiencies (means ± SEM, n=8) in MDCK II cells. Statistical significance was 279 determined by Kruscal-Wallis and Dunn’s post-hoc tests. d. Left Y-axis: % PV-transduction 280 efficiencies in (pre-)treated MDCK II cells (means ± SEM, n=4). Right Y-axis: % cell viability 281 (means ± SEM, n=3).  282 
Figure 2: a. Up-/down-regulated (green/red) transcripts identified by microarrays in late- 283 versus early-passaged MDCKs. Red box: membrane protein-encoded transcript. b. mRNA 284 expression levels (means ± SEM, n=4) of DLA-DRA/-DRB1. Significance was calculated by 285 one-way ANOVA and Tukey’s tests (***p=0.0006; ****p<0.0001). c. HLA-DR schematic 286 (Motifolio). d. Left Y-axis: H17-PV transduction efficiencies in human cell lines [n=4; box-plot 287 (top/bottom: min/max values; middle band: median)]. Right Y-axis (line):  HLA-DRA mRNA 288 copies (n=4). e. FACS analysis of HLA-DR cell surface expression (representative of two 289 independent experiments). Blue and red peaks represent HLA-DR- and -DR+ subpopulations. f. 290 FACS analysis of HLA-DR expression in HEK293T/17 cells transfected with HLA-DRαβ 291 plasmids (n=2). Right top corner: immunofluorescence confirming HLA-DR expression (n=2; 292 Scale bar=10 μm). g. PV-transduction efficiencies (means ± SEM, n=4) in FACS-sorted DR-, 293 unsorted (DR+ & DR-) and FACS-sorted DR+ HEK293T/17 cells. Significance was calculated by 294 one-way ANOVA and Tukey’s tests (****p<0.0001). h. Left: PV-transduction efficiencies 295 (means ± SD, n=3) in Raji cells transfected with siControl or siHLA-DRA. Significance was 296 
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calculated with a t-test (Holm-Sidak-adjusted) and right: corresponding western blot and 297 qRT-PCR data showing HLA-DRA protein and mRNA levels (means ± SD, n=3). qRT-PCR 298 significance was calculated by two-sided t-test (p=0.0065). i. % PV-transduction levels 299 (means ± SD, n=3) in Raji cells pre-incubated with MHC-II monoclonal antibody. Significance 300 was calculated by one-way ANOVA and Dunnett’s tests (***p=0.0003, ****p<0.0001). 301  302 
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